It wasn’t just Denver
Broncos fans who had a
bad week. These three
health-care stocks got
blown away, too.
Source: Wikimedia Commons
Affymetrix (Nasdaq: AFFX)
Shares of this life-science tools and molecular diagnostic
manufacturer tanked more than 23% this week.
Why Affymetrix was so horrendous
• The company announced
disappointing Q4 earnings
results after hours on Feb. 5.
• Analysts expected adjusted
earnings of $0.07 per share,
while the actual result was
$0.02 per share.
Medidata Solutions (Nasdaq: MDSO)
The stock of the cloud-based clinical research software developer
dropped nearly 18% for the week.
Why Medidata was so horrendous
• Q4 results were solid, but
• Full-year earnings were projected
at $0.74-$0.79 per share, while
analysts expected $0.83 per
share. Not a huge miss, but
enough to waylay shares of this
Vanda Pharmaceuticals (Nasdaq: VNDA)
The small drugmaker’s shares fell 14% this week.
Why Vanda was so horrendous
• It won FDA approval on Jan. 31 for
Hetlioz in treating a rare sleep
disorder that affects blind people. A
conference call on Feb. 3 didn’t
reveal pricing, but Vanda said the
cost would be consistent with other
• Investors were probably nervous
about the potential for Hetlioz to be
too expensive to win significant
Best shot at bouncing back?
• The nod goes to Vanda.
• There’s a potential U.S. market
for Hetlioz of up to 100,000
• Even moderate success for the
drug should propel Vanda shares
• The key will be how the Hetlioz
launch fares in the coming
Find out which stock The Motley Fool’s chief
investment officer selected as the top pick for
2014 in our free report!